What is the maximum recommended daily dose of guaifenesin (expectorant) for an adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Daily Dose of Guaifenesin for Adults

Adults can take up to 2,400 mg of guaifenesin in a 24-hour period, administered as 400 mg every 4 hours (maximum 6 doses daily). 1

FDA-Approved Dosing Parameters

The FDA labeling establishes clear dosing limits for guaifenesin in adults 1:

  • Standard dose range: 10-20 mL (equivalent to 200-400 mg) every 4 hours 1
  • Maximum frequency: Not more than 6 doses in any 24-hour period 1
  • Calculated maximum: 400 mg × 6 doses = 2,400 mg per day 1

Extended-Release Formulation Alternative

For patients seeking dosing convenience, extended-release guaifenesin tablets provide an alternative 2, 3:

  • ER dosing: 600-1,200 mg every 12 hours 2, 3
  • Maximum daily ER dose: 2,400 mg (1,200 mg twice daily) 3
  • Bioequivalence: ER formulations are bioequivalent to corresponding immediate-release doses when given at steady state 3

The extended-release formulation eliminates the need for dosing every 4 hours while maintaining therapeutic plasma concentrations throughout the day 3.

Clinical Context and Efficacy Considerations

Guaifenesin's role as an expectorant has limited high-quality evidence supporting its effectiveness 4:

  • A rigorous 2014 randomized controlled trial found no measurable effect on sputum volume, hydration, viscosity, or elasticity when 1,200 mg extended-release guaifenesin was given twice daily for acute respiratory tract infections 4
  • An earlier 1982 objective cough-counting study demonstrated no antitussive effect, though subjective reports suggested reduced sputum thickness in 96% of guaifenesin recipients versus 54% with placebo 5
  • Clinical efficacy appears more established in chronic respiratory conditions (stable chronic bronchitis) than in acute upper respiratory infections 2

Safety Profile at Maximum Doses

Guaifenesin has a well-established favorable safety profile at recommended doses 2:

  • Common side effects: Generally mild and infrequent at therapeutic doses 2
  • Overdose potential: A fatal case report documented central nervous system depression and asystole following massive overdose (femoral blood concentration 25.0 μg/mL, far exceeding therapeutic levels) 6
  • Therapeutic dosing safety: The 2,400 mg daily maximum has been used safely in clinical trials without significant adverse events 2, 3

Practical Dosing Algorithm

For immediate symptom relief 1:

  • Start with 200-400 mg every 4 hours
  • Titrate within the 200-400 mg range based on response
  • Never exceed 6 doses (2,400 mg total) in 24 hours

For sustained symptom management 2, 3:

  • Consider extended-release formulation: 600-1,200 mg every 12 hours
  • Maximum 2,400 mg daily (1,200 mg twice daily)
  • Provides convenience and improved compliance compared to 4-hourly dosing

Critical Caveats

The 2,400 mg daily limit is absolute and should never be exceeded 1. While guaifenesin remains the only legally marketed expectorant in the United States, clinicians should counsel patients that objective evidence for its efficacy in acute respiratory infections is limited 4. The medication may provide more benefit through subjective symptom relief than through measurable changes in mucus properties 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.